ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. …
Pharmacokinetics, safety, and antitumor activity of ABRAXANE were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to …
FDA Label for Abraxane Injection, Powder, Lyophilized, For …
Dec 5, 2025 · Data from 106 patients accrued in two single arm open label studies and from 460 patients enrolled in a randomized comparative study were available to support the use of …
DailyMed - ABRAXANE- paclitaxel injection, powder, lyophilized, for ...
Oct 31, 2022 · ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is paclitaxel formulated as albumin-bound …
Abraxane: Package Insert / Prescribing Information / MOA
Jun 23, 2025 · Abraxane package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
ABRAXANE (Abraxis BioScience, LLC): FDA Package Insert
Oct 31, 2022 · ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant …
ABRAXANE® - Official Patient & Caregiver Website
Learn about ABRAXANE® and how it can help treat metastatic pancreatic cancer, metastatic breast cancer, and advanced NSCLC. See Full Prescribing Info and BOXED WARNING.
ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. …
Food and Drug Administration
Food and Drug Administration
Abraxane label includes a black box warning restricting use in patients with baseline neutrophil counts of less than 1,500 cells/mm3, and frequent peripheral blood cell counts should be …